Oncology Pharmacists Can Improve TKI Adherence Rates in Patients With CML

Share this content:
An oncology pharmacist significantly improved tyrosine kinase inhibitor adherence rates in patients with chronic myeloid leukemia.
An oncology pharmacist significantly improved tyrosine kinase inhibitor adherence rates in patients with chronic myeloid leukemia.

An oncology pharmacist-managed oral anticancer therapy program significantly improved tyrosine kinase inhibitor (TKI) adherence rates in patients with chronic myeloid leukemia (CML), a recent study published online ahead of print in the Journal of Oncology Pharmacy Practice has shown.1

Because research has indicated that non-adherence is a major contributing factor for treatment failure in patients with CML receiving imatinib, oncology pharmacists at the Kaiser Permanente Health Plan Hematology Oncology Infusion Clinic in Antioch, CA, sought to evaluate the impact of an oncology pharmacist-managed program on oral medication adherence compared with usual care in patients with CML.

For the study, the 2 researchers retrospectively analyzed data from electronic refill history and medical records of patients diagnosed with CML treated with TKIs managed by oncology pharmacists during a 6-year period compared with usual care. A total of 56 patients were evaluated, including 45 treated with imatinib.

Results showed that the group managed by oncology pharmacists had an 88.6% imatinib adherence rate compared to 65.8% in the usual care group (P = .0046).

RELATED: Dasatinib Discontinuation After 1 Year Feasible in Certain Patients With CML

Researchers found that pharmacists made 567 interventions during a total of 3432 pharmacist encounters, corresponding with an average of 10.1 interventions per patient.

Interventions were related to side- effect monitoring/management, drug interactions, TKI dose adjustment, laboratory monitoring, non-CML related drug choice, and copay assistance.

Reference

  1. Lam MSH, Cheung N. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia [published online ahead of print September 28, 2015]. J Oncol Pharm Pract. doi: 10.1177/1078155215608523.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters